IRadimed
Stock Forecast, Prediction & Price Target
IRadimed Financial Estimates
IRadimed Revenue Estimates
IRadimed EBITDA Estimates
IRadimed Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | ||
Revenue
% change YoY
| $41.81M N/A | $53.30M 27.47% | $65.56M 22.99% | Avg: $81.17M Low: $80.68M High: $81.66M avg. 23.80% | Avg: $98.90M Low: $98.30M High: $99.50M avg. 21.84% | ||
Net Income
% change YoY
| $9.32M N/A | $12.82M 37.56% | $17.19M 34.02% | Avg: $20.85M Low: $19.33M High: $21.75M avg. 21.29% | Avg: $27.39M Low: $26.76M High: $27.18M avg. 31.37% | ||
EBITDA
% change YoY
| $11.22M N/A | $15.62M 39.22% | $20.80M 33.10% | Avg: $18.73M Low: $18.62M High: $18.84M avg. -9.93% | Avg: $22.82M Low: $22.68M High: $22.96M avg. 21.84% | ||
EPS
% change YoY
| $0.76 N/A | $1.02 34.21% | $1.36 33.33% | Avg: $1.62 Low: $1.52 High: $1.71 avg. 18.74% | Avg: $2.12 Low: $2.1 High: $2.14 avg. 31.26% | ||
Operating Expenses
% change YoY
| $22.23M N/A | $25.65M 15.39% | $30.12M 17.41% | Avg: $41.51M Low: $41.26M High: $41.76M avg. 37.81% | Avg: $50.58M Low: $50.27M High: $50.88M avg. 21.84% | ||
FAQ
What is IRadimed stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 26.33% in 2025-2026.
We have gathered data from 1 analysts. Their low estimate is 19.33M, average is 20.85M and high is 21.75M.
What is IRadimed stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 22.82% in 2025-2026.
We have gathered data from 1 analysts. Their low revenue estimate is $80.68M, average is $81.17M and high is $81.66M.
What is IRadimed stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 25.00% in 2025-2026.
We have gathered data from 1 analysts. Their low earnings per share estimate is $1.52, average is $1.62 and high is $1.71.
What is the best performing analyst?
In the last twelve months analysts have been covering IRadimed stock. The most successful analyst is Frank Takkinen.